Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Hisamitsu Pharmaceutical CoFSE:4530 89 Debt-to-EBITDA is 0.21 as of Nov. 2025, which is 163% above its 10-year median of 0.08. GuruFocus rates FSE:4530 with a GF Score™ of 89/100 and a GF Value™ of 円3,237.07. Among 690 Drug Manufacturers companies, Hisamitsu Pharmaceutical Co ranks better than 88.7% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Hisamitsu Pharmaceutical Co's Debt-to-EBITDA or its related term are showing as below:
FSE:4530'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.06 Med: 0.08 Max: 0.14
Current: 0.08
During the past 13 years, the highest Debt-to-EBITDA Ratio of Hisamitsu Pharmaceutical Co was 0.14. The lowest was 0.06. And the median was 0.08.
FSE:4530's Debt-to-EBITDA is ranked better than 88.7% of 690
companies
in the Drug Manufacturers industry
Industry Median: 1.67
vs FSE:4530: 0.08
Hisamitsu Pharmaceutical Co (FSE:4530) Debt-to-EBITDA Explanation
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Hisamitsu Pharmaceutical Co Debt-to-EBITDA Related Terms
Hisamitsu Pharmaceutical Co Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FSE:4530 vs ESPR, AMPH, ETON: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Hisamitsu Pharmaceutical Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hisamitsu Pharmaceutical Co Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hisamitsu Pharmaceutical Co's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Hisamitsu Pharmaceutical Co's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Nov. 2025) EBITDA data.
Hisamitsu Pharmaceutical Co (FSE:4530) has a Debt-to-EBITDA of 0.21 as of Nov. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hisamitsu Pharmaceutical Co. This is 163% above median its historical median of 0.08. Over the past decade, Hisamitsu Pharmaceutical Co's Debt-to-EBITDA has ranged from 0.06 to 0.14. According to the industry distribution chart, Hisamitsu Pharmaceutical Co ranks #78 out of 690 companies in the Drug Manufacturers industry, placing it in the top 11.3%.
Is Hisamitsu Pharmaceutical Co's Debt-to-EBITDA too high?
Hisamitsu Pharmaceutical Co's current Debt-to-EBITDA of 0.21 is 163% above median its 10-year median of 0.08. Over the past 10 years, this metric has ranged from a low of 0.06 to a high of 0.14. The Drug Manufacturers industry median Debt-to-EBITDA is 1.67. Hisamitsu Pharmaceutical Co's value of 0.21 is 87.4% below this industry median. Based on the distribution chart, Hisamitsu Pharmaceutical Co ranks #78 out of 690 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 89/100, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Debt-to-EBITDA compare to ESPR and AMPH?
According to the Drug Manufacturers industry distribution chart, Hisamitsu Pharmaceutical Co ranks #78 out of 690 companies for Debt-to-EBITDA. This places Hisamitsu Pharmaceutical Co in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-EBITDA is 1.67. Hisamitsu Pharmaceutical Co's value of 0.21 is 87.4% below this benchmark. Historically, Hisamitsu Pharmaceutical Co's own Debt-to-EBITDA has ranged from 0.06 to 0.14 over the past decade. While the company's 10-year median is 0.08 vs. the industry median of 1.67, Hisamitsu Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.67, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hisamitsu Pharmaceutical Co's current Debt-to-EBITDA of 0.21 is 87.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Hisamitsu Pharmaceutical Co. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hisamitsu Pharmaceutical Co's current Debt-to-EBITDA is 0.21, which is 163% above median its own 10-year median of 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Hisamitsu Pharmaceutical Co (FSE:4530) has a current Debt-to-EBITDA of 0.21. The stock's GF Value™ is 円3,237.07, compared to a current price of 円3,975.00 — trading 22.8% above its estimated fair value. The current Debt-to-EBITDA is 0.21, which is 163% above median its 10-year median of 0.08 and 87.4% below the Drug Manufacturers industry median of 1.67. Hisamitsu Pharmaceutical Co's overall GF Score™ is 89/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (FSE:4530), the current Debt-to-EBITDA is 0.21 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hisamitsu Pharmaceutical Co (FSE:4530) Overvalued in 2026?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be overvalued.
The current stock price of 円3,975.00 is trading 22.8% above its estimated GF Value™ of 円3,237.07.
Key valuation signals for FSE:4530:
Debt-to-EBITDA: 0.21 (163% above median its 10-year median of 0.08)
GF Value™: 円3,237.07 vs. price of 円3,975.00 (22.8% above fair value)
Industry Position: 87.4% below the Drug Manufacturers median (#78 of 690)
No single metric tells the full story. See the FSE:4530 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
89GF Score
Get the complete analysis for FSE:4530
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FSE:4530 has been successfully added to your 
